A Phase 2 interventional study of Simulect® and Neoral® in Renal Transplantation, sponsored by Novartis Pharmaceuticals. Completed at 3 sites in France. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2014-07-25.
Sponsored by Novartis Pharmaceuticals (part of Novartis) · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
The aims of this study are to extensively study the levels of CD25-Receptors saturation and expression obtained with 2 different doses of Simulect® in combination with Neoral® (i.e to demonstrate that saturation and expression vary according to the dose of Simulect® given), and to study the levels of CD25-Receptors saturation without Neoral® and compare them to the data with Neoral®.
It will be conducted in low risk de novo adult renal transplant recipients until 12 weeks post-transplant, receiving either a cumulative dose of 40 or 80 mg of Simulect® in combination with Neoral®, or a cumulative dose of 80 mg of Simulect® in a calcineurin inhibitor free immunosuppressant therapy.
Novartis Pharmaceuticals is the lead sponsor of 2,719 studies on the registry; 222 are open to participants now.
Of its 585 completed or terminated interventional studies of FDA-regulated products, 439 (75%) have results posted.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion (Non inclusion) criteria:
Other protocol-defined inclusion/exclusion criteria may apply.
A cumulative dose of 40 mg of Simulect® (20mg at Day 0 (D0) and 20mg at Day 4 (D4)+ Neoral® + Myfortic® + corticosteroids
Drug: Simulect® · Drug: Neoral® · Drug: Myfortic® · Drug: Corticosteroids
A cumulative dose of 80 mg of Simulect® (40mg at D0 and 40mg at D4) + Neoral® + Myfortic® + corticosteroids
Drug: Simulect® · Drug: Neoral® · Drug: Myfortic® · Drug: Corticosteroids
A cumulative dose of 80 mg of Simulect® (40mg at D0 and 40mg at D4) + Certican® + Myfortic® + corticosteroids
Drug: Simulect® · Drug: Certican® · Drug: Myfortic® · Drug: Corticosteroids
Simulect® was provided to the study center in its commercial package containing a powder vial with 20 mg of active product and sterile water for injection. The solution should be used immediately after reconstitution. The infusion was prepared by adding at least 50 mL of physiologic or 5% glucose solution to the reconstituted solution (at least 100 mL for 40 mg of Simulect®). Simulect® was transported and kept in a cold environment (2-8°C) as recommended in the summary of product characteristics (SPC).
Also known as: Basiliximab
Neoral® was provided to the study center in its commercial package as 10, 25, 50 or 100 mg soft capsules in thermoformed blister packs.
Also known as: Cyclosporine microemulsion
Certican® was provided to the study center in its commercial package as 0.75, 0.5 and 0.25 mg tablets in thermoformed blister packs.
Also known as: Everolimus
Myfortic® was administered orally b.i.d. with a 12-hour interval. Tablets could be taken either with or outside meals but consistently throughout the study. To maintain the integrity of the enteric coating, tablets were not to be crushed. Myfortic® treatment was initiated either preoperatively or within 24 hours post transplantation according to local practice in each center. Starting dose was to be 2160 mg/day (1080 mg b.i.d.) for at least 2 weeks and for at most 4 weeks. Patients were then to receive 1440 mg/day (720 mg b.i.d.) until the end of the study. Myfortic® was administered as concomitant treatment to all patients, using the same regimen for all 3 study groups. It was provided to the study center in its commercial package as 180 and 360 mg gastro-resistant tablets.
Also known as: mycophenolate sodium
Corticosteroid i.v. therapy could be administered peri or per operatively according to local practice in each center with the same scheme for each patient in the center. Oral corticotherapy was to be initiated rapidly, within one week following transplantation, with a minimal dose of 20 mg/day. Thereafter, the dose was to be decreased according to local practice but oral corticosteroids were to be continued throughout the study with a minimal dose of 5 mg/day.
Area Under the Curve (AUC) of CD25 Saturation by Basiliximab From Day 0 to Day 84
CD25 saturation is the percentage of T cells expressing CD25. Mean AUC of CD25 was calculated only for patients who received two Simulect® injections.
Time frame: Day 84 (Week 12) after transplantation
Saturation Rate of CD25 Antigen Saturation by Basiliximab
CD25 saturation is the percentage of T cells expressing CD25
Time frame: Day 0, Day 1, Day 4, Day 6, Day 14, Day 21, Day 28, Day 42, Day 56 and Day 84 (Week 12) post-transplantation
AUC of Basiliximab Binding to CD25 Receptors From Day 0 to Day 84
Mean AUC was calculated only for patients who received two Simulect injections.
Time frame: Day 84 (Week 12) post-transplantation
Percentage of T-cells That Bind Basiliximab to CD25 Receptors
This is the percentage of T cells binding basiliximab at all timepoints.
Time frame: Day 0, Day 1, Day 4, Day 6, Day 14, Day 21, Day 28, Day 42, Day 56 and Day 84 (Week 12) post-transplantation
Proportion of CD3+, CD4+, CD8+, CD19+ and CD56+ T Cells
Cell counts of various subpopulations of T, B and NK lymphocytes (CD3, CD4, CD8, CD19 and CD56) (flow cytometry).
Time frame: Day 0, Day 6, Day 42, Day 84 (Week 12)
Percentage of Participants With of Biopsy Proven Acute Rejection (BPAR)
BPAR is one of the components of treatment failure. One assessment of efficacy was BPAR. Renal graft biopsies were performed and the renal tissue was examined to determine if there was acute rejection of the renal transplant.
Time frame: Day 84 (Week 12), Week 24 post-transplantation
Percentage of Participants With Biopsy Proven Acute Rejection (BPAR) According to Type and Severity
Antibody mediated acute rejection: C4d deposition, presence of circulating antidonor antibody, morphologic evidence of acute tissue injury such as acute tubular necrosis-like minimal inflammation or capillary and/or glomerular inflammation and/or thromboses or arterial inflammation. Cellular acute rejection: acute T-cell mediated rejection Type IA: Significant interstitial infiltration (\> 25% of parenchyma) and foci of moderate tubulitis (\> 4 mononuclear cells/tubular cross section or group of 10 tubular cells) Type IB: Significant interstitial infiltration (\> 25% of parenchyma) and foci of severe tubulitis (\> 10 mononuclear cells/tubular cross section or group of 10 tubular cells) Type IIA: Mild to moderate intimal arteritis. Type IIB: Severe intimal arteritis comprising \> 25% of the lumenal area. Type III: Transmural (full vessel wall thickness) arteritis and/or arterial fibrinoid change and necrosis of medial smooth muscle cells (with accompanying lymphocytic inflammation).
Time frame: Day 84 (Week 12), Week 24 post-transplantation
Percentage of Participants With of Treatment Failures
Treatment failure was defined either as a BPAR, a graft loss, a death or a loss to follow-up. An extended treatment failure was also defined including treated borderline lesions, BPAR, graft loss, death or loss to follow-up. Treated borderline lesions were considered as acute rejection by investigators and DMC experts.
Time frame: Day 84 (Week 12), Week 24
Estimated Glomerular Filtration Rate (eGFR) at Day 8 and Week 24
(MDRDa formula) with imputation by last observation carried forward (LOCF)
Time frame: Day 8, Week 24
With premature end of recruitment only 16 patients were included. Descriptive analysis was done \& statistical method fitted the small number of patients. One final analysis was performed at M6 post-transplantation \& comprised assessment of criteria planned at M3 and M6. Some analysis pertaining to the secondary objectives were not performed.
| Milestone | Simulect 40mg + Neoral + Myfortic + Steroids | Simulect 80mg + Neoral + Myfortic + Steroids | Simulect 80mg + Certican + Myfortic + Steroids |
|---|---|---|---|
| Started | 3 | 6 | 7 |
| Completed | 2 | 6 | 4 |
| Not completed | 1 | 0 | 3 |
| Withdrew: Adverse event | 1 | 0 | 2 |
| Withdrew: Lack of efficacy | 0 | 0 | 1 |
CD25 saturation is the percentage of T cells expressing CD25. Mean AUC of CD25 was calculated only for patients who received two Simulect® injections.
| Weeks * Percentage of saturated CD25 | Simulect 40mg + Neoral + Myfortic + Steroids | Simulect 80mg + Neoral + Myfortic + Steroids | Simulect 80mg + Certican + Myfortic + Steroids |
|---|---|---|---|
| Area Under the Curve (AUC) of CD25 Saturation by Basiliximab From Day 0 to Day 84 | 8.4 ± 1.61 | 11.1 ± 1.12 | 9.7 ± 0.70 |
CD25 saturation is the percentage of T cells expressing CD25
| percentage of T cells | Simulect 40mg + Neoral + Myfortic + Steroids | Simulect 80mg + Neoral + Myfortic + Steroids | Simulect 80mg + Certican + Myfortic + Steroids |
|---|---|---|---|
| Day 0 (before injection) | 0.0 ± 0.00 | 0.0 ± 0.00 | 0.0 ± 0.00 |
| Day 0 (2 hours after injection) | 93.7 ± 10.97 | 96.7 ± 8.16 | 94.7 ± 5.19 |
| Day 1 | 95.7 ± 7.51 | 97.7 ± 5.24 | 99.0 ± 2.65 |
| Day 4 (before injection); (n= 3, 6, 6) | 100.0 ± 0.00 | 96.2 ± 6.88 | 93.7 ± 9.89 |
| Day 4 (2 hours after injection): (n= 3, 6, 5) | 96.7 ± 5.77 | 96.3 ± 6.83 | 84.8 ± 19.25 |
| Day 6: (n= 3, 6, 6) | 98.7 ± 2.31 | 100.0 ± 0.00 | 94.0 ± 14.70 |
| Day 14: (n= 3, 6, 6) | 98.3 ± 2.89 | 96.7 ± 7.23 | 97.3 ± 6.53 |
| Day 21: (n= 3, 6, 6) | 100.0 ± 0.00 | 94.5 ± 10.80 | 92.5 ± 11.83 |
| Day 28: (n= 3, 6, 6) | 95.3 ± 4.16 | 100.0 ± 0.00 | 92.7 ± 9.33 |
| Day 42: (n= 3, 6, 5) | 78.3 ± 9.07 | 100.0 ± 0.00 | 99.2 ± 1.79 |
| Day 56: (n= 3, 6, 5) | 65.0 ± 56.35 | 93.3 ± 13.20 | 94.2 ± 12.97 |
| Day 84 (Week 12): (n= 3, 6, 5) | 0.0 ± 0.00 | 67.5 ± 48.55 | 14.2 ± 20.86 |
Mean AUC was calculated only for patients who received two Simulect injections.
| Weeks * Percentage of T cells | Simulect 40mg + Neoral + Myfortic + Steroids | Simulect 80mg + Neoral + Myfortic + Steroids | Simulect 80mg + Certican + Myfortic + Steroids |
|---|---|---|---|
| AUC of Basiliximab Binding to CD25 Receptors From Day 0 to Day 84 | 7.0 ± 1.80 | 9.9 ± 2.22 | 8.4 ± 0.75 |
This is the percentage of T cells binding basiliximab at all timepoints.
| Percentage of T cells | Simulect 40mg + Neoral + Myfortic + Steroids | Simulect 80mg + Neoral + Myfortic + Steroids | Simulect 80mg + Certican + Myfortic + Steroids |
|---|---|---|---|
| Day 0 (before injection) | 0.0 ± 0.00 | 0.0 ± 0.00 | 4.7 ± 12.47 |
| Day 0 (2 hours after injection) | 95.3 ± 8.08 | 96.2 ± 9.39 | 81.6 ± 28.30 |
| Day 1 (n= 3, 5, 7) | 70.0 ± 28.58 | 64.8 ± 35.15 | 91.4 ± 11.65 |
| Day 4 (before injection): (n= 3, 6, 6) | 100.0 ± 0.00 | 59.0 ± 45.98 | 53.0 ± 33.33 |
| Day 4 (2 hours after injection): (n= 3, 5, 5) | 100.0 ± 0.00 | 83.4 ± 20.14 | 81.2 ± 16.02 |
| Day 6: (n= 3, 6, 6) | 91.7 ± 14.43 | 99.0 ± 2.45 | 98.3 ± 4.08 |
| Day 14: (n= 3, 6, 6) | 100.0 ± 0.00 | 89.0 ± 22.00 | 93.8 ± 15.11 |
| Day 21: (n= 3, 6, 6) | 89.0 ± 19.05 | 87.7 ± 26.93 | 85.8 ± 32.31 |
| Day 28: (n= 3, 6, 6) | 76.3 ± 17.62 | 91.0 ± 14.00 | 82.7 ± 26.29 |
| Day 42: (n= 3, 6, 5) | 47.3 ± 28.22 | 84.0 ± 19.75 | 78.8 ± 30.11 |
| Day 56: (n= 3, 6, 5) | 53.0 ± 41.80 | 88.8 ± 27.35 | 75.2 ± 15.29 |
| Day 84 (Week 12): (n= 3, 6, 5) | 6.7 ± 6.11 | 57.7 ± 43.83 | 15.8 ± 9.73 |
Cell counts of various subpopulations of T, B and NK lymphocytes (CD3, CD4, CD8, CD19 and CD56) (flow cytometry).
| 10^9 cells/L | Simulect 40mg + Neoral + Myfortic + Steroids | Simulect 80mg + Neoral + Myfortic + Steroids | Simulect 80mg + Certican + Myfortic + Steroids |
|---|---|---|---|
| CD3 cells count at Day 0 (before injection) | 0.5 ± 0.25 | 0.9 ± 0.28 | 0.7 ± 0.28 |
| CD3 cells count at Day 6: (n= 3, 6, 6) | 0.6 ± 0.39 | 1.1 ± 0.50 | 0.9 ± 0.75 |
| CD3 cells count at Day 42: (n= 3, 6, 5) | 0.5 ± 0.09 | 1.2 ± 0.96 | 1.1 ± 1.18 |
| CD3 cells count at Day 84 (Week 12): (n= 3, 6, 6) | 0.8 ± 0.58 | 1.2 ± 0.72 | 1.1 ± 1.22 |
| CD4 cells count at Day 0 (before injection) | 0.4 ± 0.19 | 0.6 ± 0.20 | 0.5 ± 0.22 |
| CD4 cells count at Day 6: (n= 3, 6, 6) | 0.5 ± 0.30 | 0.7 ± 0.28 | 0.6 ± 0.59 |
| CD4 cells count at Day 42: (n= 3, 6, 5) | 0.3 ± 0.08 | 0.8 ± 0.53 | 0.8 ± 0.82 |
| CD4 cells count at Day 84 (Week 12): (n= 3, 6, 6) | 0.6 ± 0.36 | 0.8 ± 0.42 | 0.7 ± 0.86 |
| CD8 cells count at Day 0 (before injection) | 0.1 ± 0.05 | 0.3 ± 0.13 | 0.2 ± 0.15 |
| CD8 cells count at Day 6: (n= 3, 6, 6) | 0.2 ± 0.08 | 0.3 ± 0.25 | 0.2 ± 0.24 |
| CD8 cells count at Day 42: (n= 3, 6, 5) | 0.1 ± 0.05 | 0.3 ± 0.44 | 0.4 ± 0.37 |
| CD8 cells count at Day 84 (Week 12): (n= 3, 6, 6) | 0.2 ± 0.24 | 0.3 ± 0.32 | 0.3 ± 0.37 |
| CD19 cells count at Day 0 (before injection) | 0.1 ± 0.08 | 0.1 ± 0.10 | 0.1 ± 0.05 |
| CD19 cells count at Day 6: (n=3, 6, 6) | 0.1 ± 0.07 | 0.2 ± 0.27 | 0.2 ± 0.17 |
| CD19 cells count at Day 42: (n= 3, 6, 5) | 0.1 ± 0.09 | 0.2 ± 0.21 | 0.2 ± 0.18 |
| CD19 cells count at Day 84 (Week 12): (n= 3, 6, 6) | 0.2 ± 0.20 | 0.1 ± 0.11 | 0.1 ± 0.15 |
| CD56 cells count at Day 0 (before injection) | 0.1 ± 0.20 | 0.2 ± 0.14 | 0.2 ± 0.31 |
| CD56 cells count at Day 6: (n= 3, 6, 6) | 0.1 ± 0.00 | 0.1 ± 0.06 | 0.2 ± 0.25 |
| CD56 cells count at Day 42: (n= 3, 6, 5) | 0.1 ± 0.05 | 0.2 ± 0.10 | 0.2 ± 0.13 |
| CD56 cells count at Day 84 (Week 12): (n= 3, 6, 6) | 0.1 ± 0.05 | 0.1 ± 0.03 | 0.1 ± 0.15 |
BPAR is one of the components of treatment failure. One assessment of efficacy was BPAR. Renal graft biopsies were performed and the renal tissue was examined to determine if there was acute rejection of the renal transplant.
| Percentage of participants | Simulect 40mg + Neoral + Myfortic + Steroids | Simulect 80mg + Neoral + Myfortic + Steroids | Simulect 80mg + Certican + Myfortic + Steroids |
|---|---|---|---|
| Day 84 (Week 12): No | 66.7 | 83.3 | 42.9 |
| Day 84 (Week 12):Yes | 33.3 | 16.7 | 57.1 |
| Week 24: No | 66.7 | 83.3 | 42.9 |
| Week 24:Yes | 33.3 | 16.7 | 57.1 |
Antibody mediated acute rejection: C4d deposition, presence of circulating antidonor antibody, morphologic evidence of acute tissue injury such as acute tubular necrosis-like minimal inflammation or capillary and/or glomerular inflammation and/or thromboses or arterial inflammation. Cellular acute rejection: acute T-cell mediated rejection Type IA: Significant interstitial infiltration (\> 25% of parenchyma) and foci of moderate tubulitis (\> 4 mononuclear cells/tubular cross section or group of 10 tubular cells) Type IB: Significant interstitial infiltration (\> 25% of parenchyma) and foci of severe tubulitis (\> 10 mononuclear cells/tubular cross section or group of 10 tubular cells) Type IIA: Mild to moderate intimal arteritis. Type IIB: Severe intimal arteritis comprising \> 25% of the lumenal area. Type III: Transmural (full vessel wall thickness) arteritis and/or arterial fibrinoid change and necrosis of medial smooth muscle cells (with accompanying lymphocytic inflammation).
| Percentage of participants | Simulect 40mg + Neoral + Myfortic + Steroids | Simulect 80mg + Neoral + Myfortic + Steroids | Simulect 80mg + Certican + Myfortic + Steroids |
|---|---|---|---|
| Day 84 (Week 12): Antibody mediated AR - No | 66.7 | 100.0 | 85.7 |
| Day 84 (Week 12): Antibody mediated AR - Yes | 33.3 | 0.0 | 14.3 |
| Day 84 (Week 12): Cellular AR - No | 100.0 | 83.3 | 57.1 |
| Day 84 (Week 12): Cellular AR - Yes | 0.0 | 16.7 | 42.9 |
| Day 84 (Week 12): Banff type lA | 0.0 | 0.0 | 14.3 |
| Day 84 (Week 12): Banff type lB | 0.0 | 16.7 | 14.3 |
| Day 84 (Week 12): Banff type llA | 0.0 | 0.0 | 0.0 |
| Day 84 (Week 12): Banff type llB | 0.0 | 0.0 | 14.3 |
| Day 84 (Week 12): Banff type lll (C AR) | 0.0 | 0.0 | 0.0 |
| Week 24: Antibody mediated AR - No | 66.7 | 100.0 | 85.7 |
| Week 24: Antibody mediated AR - Yes | 33.3 | 0.0 | 14.3 |
| Week 24: Cellular AR - No | 100.0 | 83.3 | 57.1 |
| Week 24: Cellular AR - Yes | 0.0 | 16.7 | 42.9 |
| Week 24: Banff type lA | 0.0 | 0.0 | 0.0 |
| Week 24: Banff type lB | 0.0 | 16.7 | 28.6 |
| Week 24: Banff type llA | 0.0 | 0.0 | 0.0 |
| Week 24: Banff type llB | 0.0 | 0.0 | 14.3 |
| Week 24: Banff type lll | 0.0 | 0.0 | 0.0 |
Treatment failure was defined either as a BPAR, a graft loss, a death or a loss to follow-up. An extended treatment failure was also defined including treated borderline lesions, BPAR, graft loss, death or loss to follow-up. Treated borderline lesions were considered as acute rejection by investigators and DMC experts.
| Percentage of participants | Simulect 40mg + Neoral + Myfortic + Steroids | Simulect 80mg + Neoral + Myfortic + Steroids | Simulect 80mg + Certican + Myfortic + Steroids |
|---|---|---|---|
| Day84 (Week 12): BPAR and/or borderline lesions-No | 66.7 | 66.7 | 14.3 |
| Day84 (Week 12):BPAR and/or borderline lesions-Yes | 33.3 | 33.3 | 85.7 |
| Day 84 (Week 12): Graft loss - No | 66.7 | 100.0 | 100.0 |
| Day 84 (Week 12): Graft loss - Yes | 33.3 | 0.0 | 0.0 |
| Day 84 (Week 12): Death - No | 100.0 | 100.0 | 100.0 |
| Day 84 (Week 12): Death - Yes | 0.0 | 0.0 | 0.0 |
| Day 84 (Week 12): Loss to follow-up - No | 100.0 | 100.0 | 100.0 |
| Day 84 (Week 12): Loss to follow-up - Yes | 0.0 | 0.0 | 0.0 |
| Week 24: BPAR or borderline lesions - No | 66.7 | 66.7 | 14.3 |
| Week 24: Graft loss - No | 66.7 | 100.0 | 100.0 |
| Week 24: Death - No | 100.0 | 100.0 | 100.0 |
| Week 24: Loss to follow-up - No | 100.0 | 100.0 | 100.0 |
| Week 24: Loss to follow-up - Yes | 0.0 | 0.0 | 0.0 |
| Week 24: BPAR or borderline lesions - Yes | 33.3 | 33.3 | 85.7 |
| Week 24: Graft loss - Yes | 33.3 | 0.0 | 0.0 |
| Week 24: Death - Yes | 0.0 | 0.0 | 0.0 |
(MDRDa formula) with imputation by last observation carried forward (LOCF)
| mL/min/1.73m^2 | Simulect 40mg + Neoral + Myfortic + Steroids | Simulect 80mg + Neoral + Myfortic + Steroids | Simulect 80mg + Certican + Myfortic + Steroids |
|---|---|---|---|
| Day 8 | 35.0 ± 13.20 | 53.8 ± 23.79 | 49.9 ± 18.45 |
| Week 24 (n= 3, 6, 6) | 31.9 ± 27.93 | 55.7 ± 15.68 | 54.4 ± 10.48 |
Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Simulect 40mg + Neoral + Myfortic + Steroids | — | 2/3 (66.7%) | 3/3 (100%) |
| Simulect 80mg + Neoral + Myfortic + Steroids | — | 2/6 (33.3%) | 6/6 (100%) |
| Simulect 80mg + Certican + Myfortic + Steroids | — | 5/7 (71.4%) | 6/7 (85.7%) |
| Event | Simulect 40mg + Neoral + Myfortic + Steroids | Simulect 80mg + Neoral + Myfortic + Steroids | Simulect 80mg + Certican + Myfortic + Steroids |
|---|---|---|---|
| Transplant rejectionImmune system disorders | 1/3 | 0/6 | 1/7 |
| Femur fractureInjury, poisoning and procedural complications | 1/3 | 0/6 | 0/7 |
| Graft lossInjury, poisoning and procedural complications | 1/3 | 0/6 | 0/7 |
| Post procedural haematuriaInjury, poisoning and procedural complications | 1/3 | 0/6 | 0/7 |
| Renal failure acuteRenal and urinary disorders | 0/3 | 0/6 | 2/7 |
| GastritisGastrointestinal disorders | 0/3 | 1/6 | 0/7 |
| Blood creatinine increasedInvestigations | 0/3 | 1/6 | 1/7 |
| Diabetes mellitusMetabolism and nutrition disorders | 0/3 | 1/6 | 0/7 |
| CoughRespiratory, thoracic and mediastinal disorders | 0/3 | 1/6 | 0/7 |
| Peritoneal haemorrhageGastrointestinal disorders | 0/3 | 0/6 | 1/7 |
| Event | Simulect 40mg + Neoral + Myfortic + Steroids | Simulect 80mg + Neoral + Myfortic + Steroids | Simulect 80mg + Certican + Myfortic + Steroids |
|---|---|---|---|
| Oedema peripheralGeneral disorders | 3/3 | 1/6 | 1/7 |
| HypertensionVascular disorders | 2/3 | 1/6 | 4/7 |
| Cytolytic hepatitisHepatobiliary disorders | 1/3 | 3/6 | 0/7 |
| AnaemiaBlood and lymphatic system disorders | 1/3 | 2/6 | 2/7 |
| NeutropeniaBlood and lymphatic system disorders | 0/3 | 2/6 | 0/7 |
| ThrombocytopeniaBlood and lymphatic system disorders | 1/3 | 0/6 | 0/7 |
| AscitesGastrointestinal disorders | 1/3 | 0/6 | 0/7 |
| Gingival hypertrophyGastrointestinal disorders | 1/3 | 1/6 | 0/7 |
| CholestasisHepatobiliary disorders | 1/3 | 0/6 | 0/7 |
| Complications of transplanted kidneyInjury, poisoning and procedural complications | 1/3 | 0/6 | 1/7 |
| Age, Continuous(years) | Simulect 40mg + Neoral + Myfortic + Steroids | Simulect 80mg + Neoral + Myfortic + Steroids | Simulect 80mg + Certican + Myfortic + Steroids | Total |
|---|---|---|---|---|
| Mean | 53.7 ± 8.7 | 45.0 ± 11.4 | 39.7 ± 12.2 | 44.3 ± 11.9 |
| Sex: Female, Male(Participants) | Simulect 40mg + Neoral + Myfortic + Steroids | Simulect 80mg + Neoral + Myfortic + Steroids | Simulect 80mg + Certican + Myfortic + Steroids | Total |
|---|---|---|---|---|
| Female | 0 | 2 | 2 | 4 |
| Male | 3 | 4 | 5 | 12 |
The record gives a start of Mar 2012, a primary completion of Mar 2013 and a completion of Mar 2013. It does not say whether these dates are actual or estimated.
Results were first posted in Jul 2014, 1 year 4 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jun 2014. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Cyclosporine · Everolimus